Impact Of Type 2 Diabetes Mellitus On Activated Partial Thromboplastin Time and Serum Fibrinogen In Non-dialysis Chronic Kidney Disease Patients

Background: due to abnormalities in coagulation and hypo-fibrinolysis, diabetes mellitus is linked to an increased risk of thrombotic complications. In patients with chronic kidney disease (CKD), pro-and anti-hemostatic factors are disrupted, leading to both bleeding and thrombotic complications. However, few studies have shown how diabetes mellitus affects serum fibrinogen levels and APTT in non-dialysis CKD patients. Aim of the work: To investigate impact of type 2 DM on APTT and serum fibrinogen in Non-dialysis CKD patients. Patients and methods: 150 patients classified into 3 groups each group included 50 patients, group with DM only patients, group with CKD only patients and group with CKD and DM patients , demographic data, APTT, serum fibrinogen , HbA1c and eGFR were done for all patients. Results: Combining DM with CKD led to a significant increase in serum fibrinogen level (p<0.0001) and a reduction in APTT (p<0.0001). Serum fibrinogen also showed a positive correlation with HbA1c and eGFR (p<0.0001, r = 0.8) (P <0.002, r = 0.26) and a negative correlation (P<0.0001, r = -0.66) ( P< 0.0001, r = - 0.50) with HbA1c and eGFR. Conclusion: Serum fibrinogen, APTT, and glycemic state should all be closely watched in non-dialysis CKD patients. This can help lower the risk of thrombosis in the future.